Controversies Regarding Subclinical Leaflet Thrombosis After TAVR
Published: 25 February 2021
15m 20sPart 1 Subclinical leaflet thrombosis after TAVR: Numbers and facts Jolanta Siller-Matula
10m 22sPart 2 | Session 1 PRO Mamas A Mamas
10m 45sPart 2 | Session 2 CONTRA Poonam Velagapudi
13m 38sPart 2 | Session 3 Panel discussion & Audience Questions Jolanta Siller-Matula, Mamas A Mamas, Poonam Velagapudi, Kimberly Atianzar, Renate B Schnabel
A substantial number of patients develop a subclinical leaflet thrombosis (SLT) after transcatheter aortic valve replacement (TAVR).
The thrombus forms on the leaflets, which can lead to valve dysfunction and possibly to early valve degeneration. Multidetector computed tomography is the most sensitive imaging technique at detecting SLT.
Patients on antiplatelet drugs are at higher risk to develop SLT as compared to those on anticoagulants. During the live debate, the experts in the field will discuss controversies concerning SLT, including the routine use of oral anticoagulants and CT exams after TAVR.
- To learn about the natural history, incidence and clinical implications of SLT
- To learn about the mechanisms that may lead to SLT
- To understand the diagnostic criteria SLT
- To discuss the prevention and treatment options for SLT
- Interventional cardiologists with focus on TAVR procedures
- Cardiac Imaging specialists (Echocardiography, Computer Tomography)
- General cardiologists
- Specialists interested in management of antithrombotic therapies after TAVR
More from this programme
Subclinical leaflet thrombosis after TAVR: Numbers and facts
Debate: Patients should receive routine CT screening after TAVR to exclude subclinical valve thrombosis
Kimberly Atianzar, MD, is a Director, Structural Heart Program Director, Structural Imaging Assistant Professor of Medicine Medical College of Georgia at Augusta University, Augusta, GA Editor for the Fellows and Early Career Structuralists Forum for Structural Heart: Journal of the Heart Team.